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ABSTRACT:  41 
 42 
Background: Antibiotic use can have negative unintended consequences including disruption of the 43 
human microbiota which is thought to protect against pathogen overgrowth. We conducted a 44 
systematic review to assess whether there is an association between exposure to antibiotics and 45 
subsequent risk of community-acquired infections. 46 
 47 
Methods: We searched MEDLINE, EMBASE and Web of Science for studies published before 48 
30/06/2017 examining the association between antibiotic use and subsequent community-acquired 49 
infection. Infections caused by Clostridium difficile and fungal organisms were excluded. Studies 50 
focussing exclusively on resistant organism infections were also excluded.    51 
 52 
Results: Eighteen of 22,588 retrieved studies met the inclusion criteria. From these, 16 studies 53 
reported a statistically significant association between antibiotic exposure and subsequent risk of 54 
community-acquired infection. Infections associated with prior antibiotic use included Campylobacter 55 
jejuni infection (1 study), recurrent furunculosis (1), invasive Haemophilus influenzae type b infection 56 
(1), infectious mastitis (1), meningitis (1),  invasive pneumococcal disease (1),  Staphylococcus aureus 57 
skin infection (1), typhoid fever (2), recurrent boils and abscesses (1), upper respiratory tract infection 58 
and urinary tract infection (1), and salmonella infection (5), although in 3 studies on salmonella 59 
infection the effect was of marginal statistical significance.  60 
  61 
Conclusions:  We found an association between prior antibiotic use and subsequent risk of a diverse 62 
range of community-acquired infections.   Gastrointestinal, and skin and soft tissue infections were 63 
most frequently found to be associated with prior antibiotic exposure. Our findings support the 64 
hypothesis that antibiotic use may predispose to future infection risk, including infections caused by 65 
both antibiotic-resistant and non-resistant organisms. 66 
 67 
INTRODUCTION 68 
Antibiotics are an important weapon in our fight against bacterial infections. Antibiotic use is 69 
associated with recognised harms and among them is emergence of antibiotic resistant organisms.1  70 
There is concern that straightforward infections that are currently easy to control may become 71 
untreatable in the future. The growing threat of antimicrobial resistance has been declared a global 72 
public health crisis.2 Much attention has been focussed on limiting inappropriate antibiotic usage as a 73 
strategy to control drug resistance, particularly in primary care, where 90% of antibiotic prescriptions 74 
are issued.1 Even so, in the UK, most general practices continue to prescribe antibiotics at rates in 75 
excess of what is clinically justified.3   76 
Antibiotic therapy can have further unintended consequences, other than selection of resistant 77 
microorganisms. The human microbiota is a complex community of up to one hundred trillion 78 
microorganisms lining hosts’ epithelial surfaces exposed to the outside world.4 The microbiota 79 
influences human health through its role in a diverse range of physiological functions,4 including a 80 
protective role in defence against pathogens. The microbiota is thought to contribute to development 81 
of the host’s immune system and its response to infection.5 The huge range of organisms in the 82 
microbiota, commensals and potential pathogens, compete with each other for attachment sites and 83 
nutrients thereby preventing pathogen overgrowth.6 Exposure to antibiotics can change the 84 
composition of the microbiota, reducing microbial diversity and allowing the overgrowth of potentially 85 
harmful microorganisms.6 Short-term antibiotic treatment for Helicobacter pylori eradication, for 86 
example, reduces microbial diversity in the human throat and gut microbiota which in some cases 87 
persists for up to four years.7  88 
The question arises whether antibiotics prescribed to treat an acute bacterial infection could 89 
paradoxically predispose to future infections due to collateral damage inflicted on the microbiota? 90 
Clostridium difficile associated diarrhoea is a well-recognised example of an infection resulting from 91 
pathogenic colonisation of a microbial community disrupted by recent antibiotic use.8, 9 Antibiotic 92 
treatment is also associated with increased risk of fungal infection.10-12 Are there other medium and 93 
long-term infection risks associated with antibiotic use unrelated to increased resistance, or infection 94 
with Clostridium difficile or opportunist fungi? The current systematic review sought evidence of the 95 
association between antibiotic use and subsequent risk of infection in the community setting, 96 
unrelated to these previously known infection risks. 97 
OBJECTIVES: 98 
To examine whether exposure to antibiotic therapy is associated with subsequent increased risk of 99 
community-acquired infections.  100 
METHODS 101 
Procedures used in this review were consistent with Preferred Reporting Items for Systematic Reviews 102 
and Meta-Analyses (PRISMA) guidelines.13  103 
Protocol and registration: 104 
A review protocol was submitted in advance to PROSPERO which is a database of systematic review 105 
protocols (registration ID: CRD42016048521).14 106 
Eligibility Criteria:  107 
Our inclusion criteria were: (i) studies, of any design, evaluating risk of community-acquired infection 108 
associated with prior antibiotic usage; (ii) human participants, of any age, in the community setting; 109 
(iii) studies that assessed risk of infection associated with prior antibiotic exposure compared with the 110 
risk of infection without prior antibiotic exposure, in the same period (iv) the endpoint was any 111 
community-acquired infection. Our exclusion criteria were; (i) studies focussed on immune-112 
compromised patient groups (e.g. patients with human immunodeficiency virus) as these would not 113 
be representative of the general population; (ii) studies focussing on infections that are known to be 114 
associated with prior antibiotic exposure including fungal infection10-12 and Clostridium difficile 115 
infection;9 (iii) studies focussing exclusively on infections caused by antibiotic-resistant organisms as 116 
these have been the subject of a previous systematic review.15 Furthermore, these studies would not 117 
provide a true estimate of the overall risk of infection following antibiotic exposure because infections 118 
resulting from non-resistant organisms would be excluded; (iv) studies assessing the risk of nosocomial 119 
infections because their relationship with prior antibiotic use could be confounded by other factors 120 
(e.g. vulnerable patients, infectious contacts, invasive procedures); (v) non-English language articles; 121 
(vi) reviews, letters, editorials and case reports; (vii) studies assessing impact of prior antibiotic use on 122 
complications resulting from a specific infection (e.g. mortality rate); (viii) studies examining use of 123 
antibiotics as a prophylactic measure to prevent a specific infection (e.g. post-operative wound 124 
infection) because such studies are not designed to assess the impact of the antibiotic exposure on 125 
the subsequent risk of acquiring other unrelated infections. 126 
Search Strategy:  127 
The initial literature search was performed on 29th April 2016. The search was repeated on 30th June 128 
2017 to identify further articles published since the date of the initial search. The databases searched 129 
were MEDLINE, EMBASE and Web of Science. No restrictions were imposed on publication period. 130 
Search terms included both text words and MESH terms. Detailed search strategies are presented in 131 
in the Supplementary Material (Table S1).  The reference lists of eligible studies and review articles 132 
were screened to identify further studies eligible for inclusion.  133 
Study Selection: 134 
Covidence software was used to facilitate screening and selection of studies.16  The first reviewer (UM) 135 
conducted the literature search, removed duplicate articles and screened titles and abstracts with 136 
respect to the eligibility criteria. Full text articles of potentially relevant studies were independently 137 
assessed for eligibility by two reviewers (UM and PW). Any disagreements were resolved through 138 
discussion and consensus.  139 
Data Extraction: 140 
One reviewer (UM) extracted data from the full texts of included studies. Extracted data were 141 
summarised in a predesigned format and were cross-checked by a second reviewer (PW). 142 
Disagreements were resolved through discussion and consensus.  143 
Data collected included the first author, publication year, country of study, study design, study 144 
objectives, participant characteristics, exposure definition (i.e. antibiotic class, length of treatment, 145 
time from exposure to infection), exposure interval (length of time prior to the infection during which 146 
antibiotic exposure was assessed), exposure ascertainment method, infection type, definition of cases 147 
and the comparison group, sample size, main outcome measure and confounding variables. The 148 
primary outcome of interest was the odds ratio (OR) for the association of infection with prior 149 
antibiotic exposure. 150 
Quality Assessment:  151 
The Newcastle Ottawa Scale (NOS), a tool for assessing the quality of non-randomised studies,17 was 152 
applied independently to each study by two reviewers (UM and PW). Any disagreements were 153 
resolved through discussion and consensus.  154 
Each study could be assigned a maximum of nine points; four for the selection domain, two for the 155 
comparability domain and three for the exposure domain. Studies assigned NOS scores of ≥7 were 156 
considered high-quality, 5-6 were considered moderate quality, and <5 were considered low quality.  157 
Data Synthesis and Analysis 158 
Our research question is broad, aiming to examine the association between past antibiotic 159 
consumption and a diverse range of infections, at different body sites, caused by a variety of different 160 
microorganisms. Quantitative pooling of results through a meta-analysis was not justified due to the 161 
high degree of clinical heterogeneity expected between studies in terms of the infection types being 162 
investigated and differences in antibiotic exposures. Any observed association between antibiotic use 163 
and subsequent infection was considered unlikely to be universal for all infection types. We have 164 
therefore reported the findings of the systematic review as a narrative (descriptive) synthesis.   165 
RESULTS  166 
Study Selection: 167 
The literature search retrieved 22,582 publications. Six additional publications were identified from 168 
the reference list of retrieved articles. After adjusting for duplicates, 21,439 publications remained. 169 
After screening by title and abstract, 21,053 publications were excluded. A full text review was 170 
conducted of 386 publications, from which 18 met the eligibility criteria and were included in the 171 
review.18-35 Detailed rationale behind the exclusion of studies is presented in Figure 1. 172 
Study Design and Participant Characteristics:  173 
Tables 1 and 2 summarise the main characteristics of the included studies. 16 studies were case-174 
control studies and two were cohort studies.  175 
The studies involved a total of 349,085 participants. Study sample sizes ranged from 10524 to 164,461 176 
participants.34 In 13 studies the hypothesis that antibiotic use would increase subsequent risk of 177 
infections was not stated19-22, 24, 26-28, 30, 32-35 and earlier antibiotic use was one amongst many other 178 
variables assessed as potential risk factors for infection.  179 
Exposure assessment and definition: 180 
Six studies ascertained exposure status from recorded prescription data.18, 19, 23, 29, 31, 34 Ten studies 181 
determined exposure status through participant interview or questionnaire.20-22, 26-28, 30, 32, 33, 35 One 182 
study interviewed both participants and their physician,24 and in one study medication data was 183 
obtained from the physician only when the participant was unsure.25  184 
Seventeen studies defined exposure as the consumption of any antibiotic medication. One study 185 
defined exposure in terms of specific antibiotic classes.31  186 
In one study the exposure status was defined as an antibiotic prescription of 6 weeks or more for 187 
acne.31 In the remaining 17 studies, exposure was not defined in terms of the duration of antibiotic 188 
course.  189 
The length of time during which antibiotic exposure was assessed prior to the infection (exposure 190 
interval) was specified in 14 out of 18 studies.18-21, 23-30, 33, 34 In these studies, the exposure interval 191 
ranged from 2 weeks to 1 year. The median exposure interval was 2.5 months. 192 
Case Definition: 193 
Fourteen studies defined infection on the basis of a positive microbiological specimen.19-27, 29, 30, 32, 33, 35 194 
Three studies defined infection on the basis of routinely recorded primary care data.18, 31, 34 One study 195 
on recurrent furunculosis did not specify how the cases were defined.28  196 
Comparison Group: 197 
In case-control studies the control group consisted of participants who did not have a confirmed 198 
history of the infection of interest. In the cohort study on patients with acne, risk of infection was 199 
compared between those who were prescribed long-term antibiotics for acne, versus those who were 200 
not.31 In the cohort study on risk of recurrent boil and abscess, antibiotic prescription rates were 201 
compared amongst participants who had a repeat consultation for a boil or abscess within 12-months, 202 
versus those who did not.34    203 
Associations between exposure and outcome: 204 
Positive and significant associations between prior antibiotic use and subsequent risk of infection were 205 
reported in 16 out of 18 studies, including one study on Campylobacter jejuni infection,26 one study 206 
on recurrent furunculosis,28 one study on invasive Haemophilus influenzae type b infection,32 one 207 
study on infectious mastitis,35 one study on meningitis,18 one study on invasive pneumococcal 208 
disease,19 one study on  Staphylococcus aureus skin infection,27 two studies on typhoid fever,30, 33 one 209 
study on recurrent boils and abscesses,34 one study on upper respiratory tract infection and urinary 210 
tract infection,31 and five studies on salmonella infection.20, 21, 23, 24, 29 The outcome measure and 95% 211 
confidence interval from each study is presented in Tables 1 and 2.  212 
Salmonella Infection 213 
Nine out of 18 studies assessed the association between antibiotic use and subsequent risk of 214 
salmonella infection.20-25, 29, 30, 33 As this was the most frequently studied infection the results are 215 
described here in further detail. Two out of nine studies focussed exclusively on cases of typhoid 216 
fever.30, 33 Both studies reported a positive and statistically significant association between prior 217 
antibiotic use and subsequent risk of typhoid fever. The remaining seven studies assessing the risk of 218 
salmonella infection did not restrict the definition of cases to typhoid fever.20-25, 29 Five out of seven 219 
studies reported a positive and significant association between prior antibiotic use and risk of 220 
salmonella infection.20, 21, 23, 24, 29 From these five studies, three studies reported 95% confidence 221 
intervals for the OR that included 1.0 at the lower end.20, 21, 23 In these studies the effect was of 222 
marginal statistical significance. We found two negative studies which did not demonstrate a 223 
statistically significant association between prior antibiotic use and subsequent risk of salmonella 224 
infection.22, 25  225 
Timing of antibiotic exposure: 226 
Four studies assessed the effect of timing of antibiotic exposure on subsequent risk of infection.18, 19, 227 
23, 29 Increased risk of community-acquired infection after antibiotic exposure was documented up to 228 
one year in three18, 23, 29 out of four studies except for one study on pneumococcal disease19 that 229 
showed an increased risk only in the following month. 230 
In the case of meningitis,18 the association between antibiotic exposure and subsequent infection risk 231 
remained statistically significant over the 12 months exposure period prior to the infection, although 232 
as the interval between exposure and subsequent infection increased, the effect size generally 233 
diminished (0-7 days: OR = 4.23, 95% CI = 3.56–5.04 | 8-30 days: 2.12, 1.86–2.42  | 31-90 days: 1.88, 234 
1.70–2.08 | 91-180 days:  1.74, 1.56–1.94 | 181-365 days: 1.93, 1.76–2.13).  235 
The ORs for the association between antibiotic exposure and risk of pneumococcal disease19 were 236 
reported separately for exposures occurring between 0-30 days, 31-60 days, and 61-90 days before 237 
the infection and were 1.9 (95% CI: 1.1–3.2), 1.6 (0.89–3.0), and 1.2 (0.60–2.5), respectively.  238 
Gradel et al.29 reported a higher antibiotic consumption rate amongst cases of salmonella infection, 239 
compared with controls, for a one year period prior to infection. The excess antibiotic consumption 240 
amongst cases remained constant during the first 30 weeks of the one year exposure period, after 241 
which it increased steadily until 2 weeks preceding the infection.  242 
In the study by Neal et al.23 the risk of salmonella infection was greater for antibiotic exposure in the 243 
preceding month (1.8, 0.9–3.8) compared with exposure in the past year (1.4, 1.0–2.1).  244 
Three studies assessed antibiotic exposure in the 12 months preceding infection, but excluded 245 
exposure occurring within the previous 7 days to account for the possibility of reverse causation. These 246 
studies demonstrated an association between previous antibiotic use and recurrent furunculosis (OR: 247 
16.6, 95% CI: 2.2–66.0),28 non-typhoid salmonella (1.59, 1.43–1.77),29 and meningitis (2.04, 1.91–248 
2.18).18 249 
Number of antibiotic prescriptions: 250 
A dose-response relationship was reported between antibiotic exposure and risk of meningitis.18 251 
Patients receiving ≥4 antimicrobials in the preceding 12 months had a higher risk of meningitis (2.85, 252 
2.44–3.34) compared to those receiving one antimicrobial prescription (1.74, 1.62–1.88).  253 
The association between invasive pneumococcal disease19 and antibiotic usage in the preceding 3 254 
months was stronger for patients who had ≥2 antibiotic prescriptions (2.1, 1.2–3.8), compared with 255 
those who had a single prescription (1.4, 0.88–2.3). 256 
Quality assessment: 257 
Seven studies were deemed to be of high quality, ten studies of moderate quality and one study of 258 
low quality (See Supplementary Material, Table S2 and S3). There was considerable variation between 259 
studies in the selection of confounding variables. The most common confounding variables were age, 260 
gender and location. Case-control studies scored poorly on method of ascertainment of exposure, 261 
mostly relying on written self-reports from participants. Non-response rates were also poorly reported 262 
in case-control studies.   263 
DISCUSSION  264 
We have found that previous antibiotic use was associated with 12 different community-acquired 265 
infections, including infections of viral and bacterial origin. The associated infections ranged from 266 
common ailments such as upper respiratory tract infection (URTI) and infectious diarrhoea, to 267 
relatively rare but potentially life-threatening infections such as meningitis. Our findings provide 268 
evidence that harms of antibiotic use could extend beyond the widely recognised threat of promotion 269 
of drug-resistant organisms, to include an increased subsequent risk of infections caused by a range 270 
of microorganisms and at many different anatomical sites.  271 
Prior antibiotic consumption and subsequent infection risk was not the primary research question in 272 
most of the included studies. Most studies assessed several potential risk factors for infection, and in 273 
these the discovery of an association between antibiotic use and subsequent infection was an 274 
unexpected finding. The novelty of this finding was not commented upon by many authors. Despite 275 
inclusion as a potential risk factor in several studies, the hypothesis that prior antibiotic therapy could 276 
increase future risk of community-acquired infection has received little attention in published 277 
literature.  278 
We did not find evidence of association between prior antibiotic use and subsequent infection in any 279 
randomised controlled clinical trials of antibiotics. This was probably for two reasons. Firstly, prior 280 
antibiotic use was not an acknowledged confounding factor. Secondly infections occurring at sites 281 
different to the target of the intervention would not have been seen as an adverse effect of the use 282 
of antibiotics. Recurrence of the target infection would have been interpreted as intervention failure, 283 
not an adverse effect of the intervention. 284 
The association between exposure to antibiotics and future infection may be explained by the 285 
disruptive effect of antibiotic therapy on the microbiota. Antibiotic-induced alteration of the 286 
microbiota could diminish the local suppressive effect of commensal organisms on pathogen 287 
overgrowth. There is evidence that the microbiota stimulates host epithelial cells to produce 288 
antimicrobial peptides36 and promotes antimicrobial activity of local immune cells.5, 37 Furthermore, 289 
the gut microbiota may modulate systemic immunity and influence host susceptibility to infections 290 
distant from the gut.38 Experimental studies have shown that microbiota-depleted mice have reduced 291 
production of inflammatory cytokines, decreased bactericidal activity of macrophages, reduced 292 
production, extravasation and bactericidal activity of neutrophils and impaired antibody response to 293 
viral infections.38 294 
If alteration of the microbiota was responsible for the increased infection risk following antibiotic 295 
therapy it might be expected that the risk of infection would return to baseline as the microbiota 296 
recovered to its pre-treatment state. Four studies analysed variation in the strength of association 297 
between prior antibiotic therapy and subsequent infection in relation to the timing of antibiotic 298 
exposure.18, 19, 23, 29 In three out of four studies  there was a trend for weakening of the association 299 
between prior antibiotic therapy and subsequent infection as the interval between antibiotic use and 300 
diagnosis of infection increased.18, 19, 29 In the case of pneumococcal disease the observed association 301 
between antibiotic exposure and risk of infection weakened to the extent that the association failed 302 
to reach statistical significance for distant exposures which occurred more than 30 days prior to the 303 
infection.19 Together these findings support the hypothesis that transient alteration of the microbiota 304 
may be responsible for mediating an increased infection risk following antibiotic exposure. One study 305 
on salmonella infection was an exception since it did not demonstrate a weakening of the association 306 
between antibiotic exposure and subsequent infection as the interval between antibiotic exposure 307 
and diagnosis of infection increased.23 308 
The risk of meningitis and invasive pneumococcal disease was found to increase with increasing 309 
number of antibiotics to which the patient was exposed prior to the diagnosis of infection.18, 19 310 
Repeated exposure to antibiotics within the exposure interval would be expected to delay the 311 
recovery of the microbiota to its pre-treatment state. This further strengthens the suspicion that 312 
antibiotic-induced alteration of the microbiota may be responsible for increased infection risk 313 
following antibiotic therapy.  314 
On the other hand the observed association between previous antibiotic exposure and subsequent 315 
infection could reflect excessive prior antibiotic consumption amongst persons with increased 316 
susceptibility to infections that was independent of the effect of antibiotic therapy on the microbiota. 317 
This susceptibility to infections could have been inherited or acquired. If this was the case, frequent 318 
antibiotic consumption above a specific threshold would be a clinically valuable marker in identifying 319 
a subset of patients that warranted further investigation for a previously unrecognised immune 320 
vulnerability.  321 
A further explanation for the observed association may lie in the variation between patients of the 322 
threshold for seeking a medical consultation for symptoms. Patients with frequent healthcare-seeking 323 
behaviour may be more likely to be diagnosed with infections, and to be prescribed antibiotics. One 324 
study controlled for frequency of medical care in their analysis and found an increased risk of URTI in 325 
patients exposed to long-term antibiotics for acne, even after adjusting for consultation frequency.31  326 
Limitations and Future work: 327 
To our knowledge, this is the first systematic review to demonstrate the association between prior 328 
antibiotic therapy and subsequent risk of community-acquired infections, other than infections 329 
caused by antibiotic resistant-organisms, fungal organisms and Clostridium difficile.  330 
The association between antibiotic use and subsequent risk of infection should be interpreted with 331 
caution. The observational nature of the included studies means it is not possible to establish causality. 332 
Most studies did not exclude antibiotic exposure occurring in the days leading up to the infection 333 
hence reverse causation should be considered as an alternative explanation for the observed 334 
association. Antibiotic exposure could have occurred as a result of prodromal symptoms of the 335 
infection under study, rather than being a distant exposure due to an unrelated illness which then 336 
increased susceptibility to the current infection.  337 
A further limitation is the possibility of confounding by indication resulting from underlying host 338 
susceptibility to infection, as described earlier. This may be addressed by designing studies which take 339 
this into account or adjust for infection susceptibility. 340 
The use of retrospective self-reports of antibiotic exposure in some studies is likely to have introduced 341 
recall bias. There was insufficient data on adherence to the prescribed course of antibiotics which 342 
could have resulted in misclassification of exposure status.  343 
Most studies did not include sufficient prescribing details to establish whether there was a dose-344 
response relationship between antibiotic usage and subsequent infection, nor whether the 345 
relationship was stronger with broad spectrum antibiotics, a finding which might have provided more 346 
support for the hypothesis of collateral microbiota damage.  347 
The studies on salmonella infection provided inconclusive evidence on whether there was an 348 
association between infection and prior antibiotic therapy. This warrants further investigation, 349 
possibly through a meta-analysis which could provide a more precise estimate of the overall effect 350 
size.   351 
A further limitation of our review was the exclusion of non-English language papers and those that 352 
met the inclusion criteria but the full text article was irretrievable. 353 
CONCLUSION 354 
Prior antibiotic therapy was associated with a diverse range of community-acquired infections. This 355 
included infections caused by antibiotic-resistant and non-resistant organisms. The association 356 
between antibiotic exposure and subsequent infection became weaker with increasing time from 357 
antibiotic exposure. The risk of infection increased with increasing number of antibiotics to which the 358 
patients were exposed. Whilst antibiotic therapy is often necessary for the treatment of bacterial 359 
infections, our findings highlight the continued need to limit inappropriate antibiotic prescriptions in 360 
primary care, both to reduce the consequences of bacterial resistance and possibly also to reduce the 361 
risk of future infections. The observed association may help clinicians in dissuading their patients from 362 
insisting on an antibiotic prescription when deemed not to be clinically indicated. New research may 363 
help discover whether other infection types, not examined by the studies included in our review, are 364 
also associated with prior antibiotic therapy. Further studies are also required to examine the 365 
mechanisms underlying the observed association, particularly whether this association could be 366 
mediated through antibiotic-induced collateral damage to the microbiota.  367 
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Additional records identified from 
reference list of full-text articles 
(n = 6) 
Records after duplicates removed 
(n =  21,439) 
Records screened 
(n = 21,439) 
Records excluded 
(n = 21,053) 
Full-text articles assessed 
for eligibility 
(n =  386) 
Full-text articles excluded, with 
reasons 
(n = 368)  
145 Resistant organism infection 
75 Nosocomial infection 
38 Fungal infection 
40 Clostridium difficile Infection 
21 Assessed impact of antibiotic 
use on infection complication 
13 Language other than English 
12 Reviews, letters, editorials and 
case reports 
8 Inappropriate control group 
12 Co-morbid condition/specific 
patient group 
4 Full text article irretrievable 
Studies included in review 
(n =  18) 
 Table 1: Data Extraction Table for Case-Control Studies (in alphabetical order of infection studied) 556 
First Author  Publication 
year;  
Country 
 
Infection 
studied 
Antibiotic;   
Exposure 
Interval 
Case definition Comparison group Sample size Fully 
adjusted 
outcome 
(95% CI) 
Confounders variables 
adjusted for 
Effler26 
 
2001; 
USA 
 
Campylobacter 
Jejuni 
Any; 
28 days. 
Lab confirmed. 
Age: not available.   
Age and telephone 
exchange matched.  
211 cases 
211 controls 
OR 3.3 
(1.1–9.6) 
Consumption of various 
food items, acid suppressing 
drugs and contact with live 
chicken.  
El-Gilany28 
 
2009; 
Egypt 
 
Furunculosis 
(recurrent) 
Any; 
1 year.   
Clinic attendants 
with ≥3 attacks of 
boils within the 
previous 12 months.  
All ages.  
Attendants of the same 
clinic diagnosed with 
furunculosis for the first 
time.  
74 cases 
74 controls. 
OR 16.6  
(2.2–66.0) 
Family history, diabetes 
mellitus, anaemia, previous 
hospitalisation, personal 
hygiene, skin diseases and 
number of lesions. 
McVernon32 
 
2008; 
UK 
 
Haemophilus 
influenzae type 
b (invasive) 
Frequency 
of previous 
antibiotic 
use  
Lab confirmed cases.  
Age: 5 years to 9 
year and 11 months.  
Matched by date of birth 
and region. 
136 cases 
295 controls 
Frequent use:  
OR 1.51  
(1.06–2.13) 
Sex, prematurity, breast fed, 
past illness, family 
demographic factors, 
bedroom sharing, smoking, 
central heating, home 
ownership, vaccination 
status. 
Mediano35 
 
2014; 
Spain 
 
Mastitis 
(infectious) 
Any; 
During 
pregnancy. 
Lab confirmed. 
Lactating females.  
Healthy breastfeeding 
women with no clinical 
symptoms of mastitis and 
negative milk culture.  
368 cases 
148 controls. 
OR 5.38 
(2.85–10.14) 
Age, personal and family 
history, infection, comorbid, 
drugs and pregnancy, 
childbirth and breastfeeding 
related factors 
Armstrong18 2016; 
UK 
Meningitis  Any; 
1 year. 
Identified from GP 
records. 
All ages. 
Matched on age, sex, 
GP practice, and index 
date.  
7346 cases 
29384 controls 
OR 2.04 
(1.91–2.18) 
13 variables including 
demographic factors, 
lifestyle, comorbidities and 
medications.  
Chun19 2015; 
USA 
 
Pneumococcal 
disease 
(invasive) 
Any; 
3 months. 
Lab confirmed. 
Age: 0-12 years.  
Matched by age, Health 
Plan membership, and 
length of membership. 
171 cases 
342 controls 
OR 1.57  
(1.06–2.33) 
Sex, race, age, risk status, 
Health Plan membership, 
and pneumococcal 
vaccination. 
Doorduyn20 
 
2016; 
Netherland 
Salmonella Any; 
4 weeks. 
Lab confirmed. 
All ages.    
Matched for age, sex, 
degree of urbanization 
and season.  
193 cases 
3119 controls 
OR 1.9 
(1.0–3.4) 
Age, sex, degree of 
urbanization and education. 
 Gradel29 
 
2008; 
Denmark 
 
Salmonella Any; 
1 year.   
Lab confirmed. 
Age: 1-99 years. 
Residents of same county 
matched for specimen 
date, gender, and age. 
1882 cases. 
18820 controls  
OR 1.59 
(1.43–1.77) 
Gender, Antibiotic Score*, 
Patient Group, Age, NTS 
infection month and 
Serovar. 
Delarocque-
Astagneau21  
2000; 
France 
Salmonella Any; 
1 month. 
Lab confirmed 
Age: <14 years.  
Matched for age and 
place of residence.  
101 cases 
101 controls 
OR 2.3 
(1.0–5.5) 
Consumption of various 
food items. 
Banatvala25 
 
1999; 
UK 
 
Salmonella Any; 
1 month. 
Lab confirmed.  
All ages.  
1. Case nominated and 
matched for age, gender 
and area of residence. 
2. Randomly selected 
from London area.  
209 cases & 
matched 
control. 
854 random 
controls. 
Matched: 
     OR 1.3 
   (0.6–2.8) 
Unmatched: 
     OR 1.3 
   (0.6–2.6) 
Not available 
Neal23 
 
1994; 
UK 
 
Salmonella Any; 
1 year. 
Lab confirmed and 
notified. 
Age ≥45 years. 
Next two patients in the 
practice records system 
matched for age and sex. 
188 cases 
376 controls 
Past year: 
OR 1.4 
(1.0–2.1) 
Gastric surgery, H2 
antagonist treatment, and 
other drug use. 
Kass22 
 
1992; 
USA 
 
Salmonella Any; 
‘Recent’. 
Lab confirmed and 
notified.   
Age ≥10 years.  
Matched for region.  120 cases 
265 controls 
OR I.96  
(0.86–4.37) 
Prior health problems and 
prior medical therapies. 
Pavia24 
 
1989; 
USA 
 
Salmonella  Any; 
30 days. 
Lab confirmed.  
Age >1 year.  
Matched for Age, 
neighbourhood and 
telephone exchange. 
35 cases 
70 controls. 
OR 3.8  
(1.2–11.9) 
Immunosuppression, use of 
antacids or H2-blocking 
agents  
Early27 
 
2012; 
Hawai 
 
S. aureus skin 
infection 
Any;  
6 months. 
Lab confirmed.  
Age: 6 months to 17 
years. 
Matched for age, 
clinician, and date of 
clinician visit. 
71 cases 
146 controls 
OR 2.90** 
(1.29–6.61) 
Household contact, 
Abrasions/wounds, skin 
disorders, weight, sharing 
bed linens and towels. 
Srikantiah33 
 
2007; 
Uzbekistan 
Typhoid fever Any; 
2 weeks. 
Lab confirmed. 
All ages.  
Age and community-
matched controls. 
97 cases 
192 controls 
OR 12.2  
(4.0–37.0) 
Occupation, consumption of 
various food and drink 
items. 
Luby30 1998; 
Pakistan 
 
Typhoid fever Any; 
2 months. 
Lab confirmed. 
All ages. 
Neighbourhood and age-
matched.  
100 cases 
200 controls  
OR 5.7 
(2.3–13.9) 
Consumption of various 
food and drink items.  
 557 
Abbreviations: NTS infection, Nontyphoid Salmonella Infection. 558 
*Antibiotic score (0 to 5); Antibiotics were classified according to their potential impact on the intestinal flora, with higher scores being associated with increasing impact on the intestinal flora. 559 
**Association reached significance For Native Hawaiians and Pacific Islanders (NHPI) ethnic category but not for the non-NHPI ethnic category (OR: 1.93, 95% CI: 0.93 to 4.01). 560 
 561 
 562 
 Table 2: Data Extraction Table for Cohort Studies 563 
First 
Author 
(Year) 
 
Publication  
Year; 
Country 
Data Source and 
Study Population 
Infection 
studied 
Exposure definition  Case definition 
and follow-up 
Comparison Sample 
size 
Fully 
adjusted 
outcome 
(95% CI) 
Confounders 
variables adjusted 
for 
Shallcross34 
 
2015;  
UK 
Registered with 
THIN participating 
GP practice, any 
age, and sought 
care for a boil, 
abscess, 
carbuncle or 
furuncle.  
Recurrent boil 
or abscess  
Antibiotic 
prescription in the 6 
months prior to  the 
date of index 
consultation  
Second 
consultation for 
a boil or abscess 
within 3 weeks 
to 12 months. 
Patients without a 
repeat 
consultation for 
boil or abscess. 
Cohort of  
164,461 
patients. 
 
10% 
developed 
a repeat 
boil or 
abscess.   
 RR 1.4 
(1.3–1.4) 
Age, Sex, BMI, 
Diabetes, Skin 
Disease, Prior 
Antibiotic, Smoking 
status. 
 
Margolis31 
 
2005; 
UK 
Registered with 
GPRD 
participating GP 
practice, aged 15 
to 35 years and 
recorded 
diagnosis of Acne 
vulgaris. 
1. Upper 
Respiratory 
Tract 
Infection 
(URTI)  
 
2. Urinary 
Tract 
Infection 
(UTI).  
Prescription >6weeks 
of oral erythromycin 
or an oral tetracycline 
or topical 
erythromycin or 
clindamycin or a 
combination of both.  
UTI or URTI 
within 12 
months after 
enrolment. 
Patients without 
acne antibiotic use 
were considered 
unexposed 
84,997 
exposed 
 
33,519 
unexposed 
URTI: 
   OR 2.23 
(2.12–2.34) 
 
UTI: 
    OR 1.10*  
 (1.01–1.19) 
Age, year of 
diagnosis, sex, 
contraceptive 
use or counselling 
(only for UTIs), 
practice, diabetes, 
asthma, visit 
frequency, and the 
number of 
prescriptions for 
acne antibiotics.  
 564 
Abbreviations: THIN, The Health Improvement Network; BMI, Body Mass Index; GPRD, General Practice Research Datalink, now known as Clinical Practice Research Datalink (CPRD). 565 
*The OR for UTI is statistically significant however the authors of the study concluded that it was not clinically meaningful 566 
